| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Sörhede Winzell, B Ahré. Glucagon-like peptide-1 and islet lipolysis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655711. |
this indicates that a lipid signal does not contribute to the acute stimulation of insulin secretion by glp-1. |
2005-05-12 |
2023-08-12 |
mouse |
| M Sörhede Winzell, B Ahré. Glucagon-like peptide-1 and islet lipolysis. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655711. |
to test whether lipolysis might be involved in the islet effects of long-term glp-1 action, mice from the two feeding groups were chronically treated with exendin-4, a peptide that lowers blood glucose by interacting with glp-1 receptors, in order to stimulate insulin secretion, for 16 days before isolation of the islets. |
2005-05-12 |
2023-08-12 |
mouse |
| G G Holz, G Hol. New insights concerning the glucose-dependent insulin secretagogue action of glucagon-like peptide-1 in pancreatic beta-cells. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655710. |
in the absence of glucose, no "fuel" is available to support atp production, and glp-1 fails to stimulate insulin secretion. |
2005-05-12 |
2023-08-12 |
human |
| D D'Alessio, T Vahl, R Prigeo. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655716. |
more controversial are potential effects of glp-1 on hepatic glucose production or storage independent of insulin and glucagon. |
2005-05-12 |
2023-08-12 |
Not clear |
| R Perfetti, H Hu. The role of GLP-1 in the life and death of pancreatic beta cells. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655712. |
administration of glp-1 to rodent models of type 2 diabetes ameliorates insulin secretion, induces the replication of islet cells, and promotes islet-cell neogenesis from pancreatic ductal cells susceptible to transdifferentiate in insulin-producing cells. |
2005-05-12 |
2023-08-12 |
human |
| B Ahré. GLP-1 and extra-islet effects. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655717. |
the main target of action of glucagon-like peptide-1 (glp-1) is the islet, where the hormone stimulates insulin secretion, promotes beta cell proliferation and neogenesis, and inhibits glucagon secretion. |
2005-05-12 |
2023-08-12 |
Not clear |
| M A Nauc. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655719. |
biological actions of glp-1 in healthy and type 2 diabetic subjects include (a) stimulation of insulin secretion in a glucose-dependent manner, (b) suppression of glucagon, (c) reduction in appetite and food intake, (d) deceleration of gastric emptying. |
2005-05-12 |
2023-08-12 |
human |
| M A Nauc. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655719. |
since the incretin effect--the higher insulin secretory response to oral as compared to intravenous glucose loads - is reduced in patients with type 2 diabetes, glp-1 has been used to pharmacologically replace incretin. |
2005-05-12 |
2023-08-12 |
human |
| J J Meier, M A Nauc. GIP as a potential therapeutic agent? Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655720. |
glucose-dependent insulinotropic polypeptide (gip) is released from k-cells in the gut after meal ingestion, and acts in concert with glucagon-like peptide 1 (glp-1) to augment glucose-stimulated insulin secretion. |
2005-05-12 |
2023-08-12 |
mouse |
| B Ahrén, O Schmit. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 36. issue 11-12. 2005-05-12. PMID:15655721. |
glucagon-like peptide-1 (glp-1) is an incretin hormone with antidiabetic action through its ability to stimulate insulin secretion, increase beta cell neogenesis, inhibit beta cell apoptosis, inhibit glucagon secretion, delay gastric emptying and induce satiety. |
2005-05-12 |
2023-08-12 |
Not clear |
| Michael A Nauck, Birgit Baller, Juris J Meie. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. vol 53 Suppl 3. 2005-04-14. PMID:15561910. |
the two hormones responsible for the incretin effect, glucose-dependent insulinotropic hormone (gip) and glucagon-like peptide-1 (glp-1), are secreted after oral glucose loads and augment insulin secretion in response to hyperglycemia. |
2005-04-14 |
2023-08-12 |
Not clear |
| Michael A Nauck, Birgit Baller, Juris J Meie. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes. vol 53 Suppl 3. 2005-04-14. PMID:15561910. |
on the other hand, this provides a basis to use incretin hormones, especially glp-1 and its derivatives, to replace a deficiency in incretin-mediated insulin secretion in the treatment of type 2 diabetes. |
2005-04-14 |
2023-08-12 |
Not clear |
| Laurie L Baggio, Jung-Guk Kim, Daniel J Drucke. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes. vol 53 Suppl 3. 2005-04-14. PMID:15561912. |
glucagon-like peptide-1 (glp-1) stimulates glucose-dependent insulin secretion and inhibits food intake, gastric emptying, and glucagon secretion, actions that promote reduction of fasting and postprandial glycemia in subjects with type 2 diabetes. |
2005-04-14 |
2023-08-12 |
mouse |
| Laurie L Baggio, Jung-Guk Kim, Daniel J Drucke. Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes. vol 53 Suppl 3. 2005-04-14. PMID:15561912. |
similarly, the levels of insulin, pdx-1, and glp-1 receptor mrna transcripts were comparable in wild-type and mt-ex-4 transgenic mice after 1 week of ex-4 administration. |
2005-04-14 |
2023-08-12 |
mouse |
| Maria Sörhede Winzell, Giovanni Pacini, Claes B Wollheim, Bo Ahré. Beta-cell-targeted expression of a dominant-negative mutant of hepatocyte nuclear factor-1alpha in mice: diabetes model with beta-cell dysfunction partially rescued by nonglucose secretagogues. Diabetes. vol 53 Suppl 3. 2005-04-14. PMID:15561929. |
in contrast, insulin responses to nonglucose secretagogues were only partially suppressed (to glp-1 [100 nmol/l] by 40%, to carbachol [1 micromol/l] by 20%, and to palmitate [0.5 mmol/l] by 15%), whereas the response to depolarization by kcl (50 mmol/l) was not reduced. |
2005-04-14 |
2023-08-12 |
mouse |
| Amal K Bose, Mihaela M Mocanu, Richard D Carr, Christian L Brand, Derek M Yello. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. vol 54. issue 1. 2005-04-14. PMID:15616022. |
glucagon-like peptide 1 (glp-1), a gut incretin hormone that stimulates insulin secretion, also activates antiapoptotic signaling pathways such as phosphoinositide 3-kinase and mitogen-activated protein kinase in pancreatic and insulinoma cells. |
2005-04-14 |
2023-08-12 |
rat |
| B Ahrén, G Pacin. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes, obesity & metabolism. vol 7. issue 1. 2005-04-12. PMID:15642070. |
several potential mediators have been suggested to be signals for the beta cells to respond to insulin resistance such as glucose, free fatty acids, autonomic nerves, fat-derived hormones and the gut hormone glucagon-like peptide-1 (glp-1). |
2005-04-12 |
2023-08-12 |
Not clear |
| B Ahrén, G Pacin. Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes, obesity & metabolism. vol 7. issue 1. 2005-04-12. PMID:15642070. |
such treatment includes stimulation of insulin secretion (sulphonylureas, repaglinide and nateglinide) and insulin sensitivity (metformin and thiazolidinediones), as well as treatment aimed at supporting the signals mediating the islet adaptation (cholinergic agonists and glp-1). |
2005-04-12 |
2023-08-12 |
Not clear |
| Shareen Forbes, May Moonan, Stephen Robinson, Victor Anyaoku, Michael Patterson, Kevin G Murphy, Mohammed A Ghatei, Stephen R Bloom, Desmond G Johnsto. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes. Clinical endocrinology. vol 62. issue 1. 2005-04-11. PMID:15638870. |
glucagon-like peptide-1 (glp-1) potentiates the insulin response to oral glucose, and its secretion is diminished in type 2 diabetes. |
2005-04-11 |
2023-08-12 |
Not clear |
| Javier Jimenez-Feltstrom, Ingmar Lundquist, Stefanie Obermuller, Albert Saleh. Insulin feedback actions: complex effects involving isoforms of islet nitric oxide synthase. Regulatory peptides. vol 122. issue 2. 2005-04-08. PMID:15380928. |
as shown biochemically and with confocal microscopy, the stimulatory action of high insulin on nos activities and the associated inhibition of c-peptide release were reversed by raising cyclic amp through addition of either glucagon-like peptide 1 (glp-1) or dibutyryl cyclic amp (bt(2)camp) to the incubated islets. |
2005-04-08 |
2023-08-12 |
Not clear |